Allergan Plc (AGN)

162.10
2.70 1.70
NYSE : Health Technology
Prev Close 159.40
Open 161.04
Day Low/High 160.05 / 162.56
52 Wk Low/High 156.00 / 256.80
Volume 1.09M
Avg Volume 2.95M
Exchange NYSE
Shares Outstanding 332.58M
Market Cap 54.56B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.74%)

Latest News

Trimming More Allergan

Our theme of the week has been to scale down in our positions with limited upside (for varying reasons) to build up our cash.

Buying More Goldman and Amazon

We do not want to see these stocks run away from us.

FDA Acceptance Of Medicines360's Filing For Supplemental New Drug Application For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg

FDA Acceptance Of Medicines360's Filing For Supplemental New Drug Application For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg

- Application Seeks to Extend Duration of Use Up to 5 Years for LILETTA -

Adding More Amazon

We are effectively swapping out shares of Allergan, Apache and GE for more Amazon.

Cutting Our 3 Most Troubled Positions in Half

We'll sell shares of Allergan, Apache and GE, which have trended lower for a year. Plus, an announcement on our annual donation to charity!

We're Likely to Give Back Some Gains, But Not All

The latest broad-market charts, plus a look at what's next for Facebook.

Weekly Roundup

Markets rebound this week.

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

We could be poised for even a further advance PROVIDED that we stay oversold.

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'

A Look Around Today's Market

As quick as last week's selloff occurred, this rebound higher has been just as fast, and we would not be surprised to see the market retest at some point.

Aegon Supervisory Board Member Dirk Verbeek To Step Down At Next AGM

Aegon Supervisory Board Member Dirk Verbeek To Step Down At Next AGM

Aegon announces that Dirk P.M.

Aegon Concludes 2017 With Solid Fourth Quarter Results

Aegon Concludes 2017 With Solid Fourth Quarter Results

Net income more than doubles driven by US tax reform Underlying earnings decrease by 5% to EUR 525 million as a result of a weakening of the US dollar; expense savings and higher fee revenue...

Trimming Allergan

We are reducing our Allergan holdings on today's strong move.

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

In this tape, weakness may just be a sign of rest and better times to come.

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?

Jim's Daily Rundown

Jim discusses our First Data Corp exit, his interview with Broadcom's CEO, Nvidia, and his Real Money article from earlier today.

Weekly Roundup

Markets extend losses in volatile week.

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Allergan Becomes #152 Most Shorted S&P 500 Component, Replacing Cardinal Health

Allergan Becomes #152 Most Shorted S&P 500 Component, Replacing Cardinal Health

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim's Daily Rundown

Jim discusses this morning's buy of Nordstrom, Allergan's earnings from yesterday and his view on a few upcoming earning reports.

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Allergan Beats Expectations, but Shares Still Pressured

The overhang of the trough earnings year and how loss of exclusivity on drugs will play out has AGN stuck in a holding pattern.

Allergan CEO: We Are Staying in Ireland

Allergan CEO: We Are Staying in Ireland

On an earnings call, Allergan's top executive rejected the possibility of moving back to the U.S. on the heels of the new tax law.

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

Maybe inverse and/or leveraged positions are perverse in nature.

The Dow's Wild Ride - 5 Things You Must Know Before the Market Opens Tuesday

The Dow's Wild Ride - 5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are swinging wildly in and out of positive territory on Tuesday, and European stocks suffer steep declines, as investors try to make sense of a market rout that has spread globally.

TheStreet Quant Rating: D+ (Sell)